| Literature DB >> 24099651 |
Miao Mo1, Weijian Zhong, Genming Zhao, Ye Ruan, Hua Zhang, Liang Shi, Dajiang Lu, Qundi Yang, Yanyun Li, Qingwu Jiang, Rui Li, Wang-Hong Xu.
Abstract
BACKGROUND: Glycosylated hemoglobin A1c (HbA1c) has been applied to identify type 2 diabetes (T2DM) in the U.S. and European countries. It has not been used in China mainly due to lack of a standardized approach to measure HbA1c, short of knowledge about racial-specific standard and deficiency of an optimal cut-off point.Entities:
Year: 2013 PMID: 24099651 PMCID: PMC3853138 DOI: 10.1186/1472-6823-13-44
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Figure 1Flow diagram of recruitment of participants.
Demographic and clinical characteristics of the participants of the study
| Age (years) | 54 (48, 61) | 54 (48, 61) | 54 (48, 60) | |
| BMI (kg/m2) | 24.0 (21.9, 26.3) | 24.2 (22.1, 26.3) | 23.9 (21.8, 26.3) | |
| WC (cm) | 82 (76, 89) | 85 (79, 90) | 80 (74, 87) | |
| SBP (mmHg) | 123 (113, 135) | 125 (115, 137) | 121 (111, 134) | |
| DBP (mmHg) | 79 (72, 85) | 80 (73, 87) | 79 (71, 83) | |
| TC (mmol/l) | 4.60 (4.00, 5.25) | 4.45 (3.87, 5.03) | 4.80 (4.14, 5.41) | |
| TG (mmol/l) | 1.35 (0.91, 2.01) | 1.40 (0.92, 2.10) | 1.31 (0.90, 1.95) | |
| HDL-C (mmol/l) | 1.30(1.10, 1.55) | 1.21 (1.03, 1.45) | 1.37 (1.17, 1.60) | |
| LDL-C (mmol/l) | 2.67 (2.20, 3.09) | 2.60 (2.18, 3.00) | 2.71 (2.29, 3.17) | |
| FPG (mmol/l) | 5.0 (4.6, 5.4) | 5.0 (4.6, 5.4) | 5.0 (4.7, 5.4) | |
| 2hPG (mmol/l)a | 6.0 (5.0, 7.1) | 5.9 (4.8, 7.1) | 6.0 (5.1, 7.1) | |
| HbA1c (mmol/mol &%) | 37 (32, 40) & 5.5 (5.1, 5.8) | 37 (32, 41) & 5.5 (5.1, 5.9) | 37 (33, 40) & 5.5 (5.2, 5.8) | |
aFor 6,422 participants who had an OGTT (2,919 men and 3,503 women). All P values were from Wilcoxon rank sum tests.
Figure 2Nonlinear relationship of HbAwith FPG and 2hPG using RCS with 4 knots.
Performance of the optimal HbAcut-points in participants by demographic and clinical characteristics
| All subjects | 52.6 | 43 (6.1) | 75.6 | 89.3 | 34.1 | 98.0 |
| Gender | ||||||
| Male | 59.0 | 43 (6.1) | 78.2 | 88.8 | 36.7 | 98.0 |
| Female | 45.9 | 43 (6.1) | 72.7 | 89.8 | 31.6 | 98.1 |
| Age | ||||||
| 35-44 | 68.8 | 40 (5.8) | 84.4 | 84.9 | 15.1 | 99.4 |
| 45-54 | 59.9 | 41 (5.9) | 85.9 | 82.5 | 23.5 | 98.9 |
| 55-64 | 51.1 | 42 (6.0) | 82.2 | 81.3 | 27.3 | 98.2 |
| 65-74 | 40.0 | 45 (6.3) | 70.0 | 91.9 | 51.1 | 96.2 |
| BMI | ||||||
| ≤23.0 | 52.9 | 43 (6.1) | 73.6 | 92.7 | 27.0 | 99.0 |
| 23.1-24.9 | 58.0 | 43 (6.1) | 75.0 | 90.1 | 32.9 | 98.2 |
| ≥25.0 | 50.6 | 43 (6.1) | 76.4 | 85.3 | 37.8 | 96.9 |
| Elevated WCa | ||||||
| No | 56.6 | 43 (6.1) | 78.9 | 91.8 | 30.2 | 99.0 |
| Yes | 50.4 | 43 (6.1) | 73.6 | 85.8 | 37.1 | 96.6 |
| Hypertensionb | ||||||
| No | 52.6 | 43 (6.1) | 76.3 | 90.6 | 29.7 | 98.7 |
| Yes | 52.7 | 43 (6.1) | 74.6 | 84.5 | 42.1 | 95.7 |
| Elevated TGc | ||||||
| No | 50.8 | 41 (5.9) | 83.2 | 83.1 | 18.3 | 99.1 |
| Yes | 53.9 | 43 (6.1) | 78.1 | 85.1 | 39.9 | 96.8 |
| Reduced HDL-Cd | ||||||
| No | 56.7 | 43 (6.1) | 72.7 | 89.6 | 31.6 | 98.0 |
| Yes | 46.4 | 43 (6.1) | 79.9 | 88.7 | 38.4 | 98.0 |
| HW phenotypee | ||||||
| No | 53.2 | 43 (6.1) | 75.3 | 90.8 | 30.0 | 98.6 |
| Yes | 51.9 | 43 (6.1) | 75.9 | 82.9 | 42.3 | 95.4 |
aWC ≥ 90 cm in men and ≥ 80 cm in women;
bSBP/DBP ≥ 140/90 mmHg or being on antihypertensive medications;
cTG ≥ 1.695 mmol/l;
dHDL-C < 1.036 mmol/l (men) and < 1.295 mmol/l (women);
ehypertriglyceridemic waist phenotype, defined as having both a high WC ( ≥ 90 cm for men, ≥ 80 cm for women) and an elevated TG level ( ≥ 1.695 mmol/l).
Performance of FPG, 2hPG and HbA1c alone and combining use of FPG (mmol/l) and HbA1c (mmol/mol) in diagnosing diabetes
| Individual test | | | | | | |
| By FPG alonea | 6,661 | 239 | 52.6 | 100.0 | 100.0 | 96.7 |
| By 2hPG aloneb | 6,422 | 215 | 100.0 | 100.0 | 100.0 | 100.0 |
| By HbA1c alonec | 6,661 | 343 | 75.6 | 89.3 | 34.1 | 98.0 |
| Combining use of FPG and HbA1c | ||||||
| All subjects | 6,661 | 380 | 83.7 | 89.3 | 36.4 | 98.0 |
| Subjects with elevated WCd | 2,810 | 239 | 83.0 | 85.8 | 39.8 | 97.8 |
| Subjects with elevated TGe | 2,385 | 269 | 87.4 | 85.1 | 42.7 | 98.2 |
| Subjects with HWf | 1,320 | 162 | 86.6 | 82.9 | 45.5 | 97.4 |
aFPG ≥ 7.0 mmol/l; b2 hPG ≥ 11.1 mmol/l; cHbA1c ≥ 43 mmol/mol (6.1%); dWC ≥ 90 cm in men, ≥ 80 cm in women; eTG ≥ 1.695 mmol/l; fhypertriglyceridemic waist phenotype, defined as having both a high WC (≥ 90 cm for men, ≥ 80 cm for women) and an elevated TG level (≥ 1.695 mmol/l).